A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Inclusion Criteria
Exclusion Criteria
Leesburg, Florida 34748-5077, United States
Winter Park, Florida 32789-4681, United States
Boerne, Texas 78006-1993, United States
CABA, C1414AIF, Argentina
Rosario, S2013OJN, Argentina
Haskovo, 6300, Bulgaria
Pazardzhik, 4400, Bulgaria
Sofia, 1606, Bulgaria
Vratsa, 3000, Bulgaria
Providencia, Región-MetropolitanadeSantiago 7500000, Chile
Jind?ich?v Hradec, 377 01, Czechia
Beer Jacob, 0073100, Israel
Guadalajara Centro, Jalisco 44100, Mexico
Krakow, 31-637, Poland
Lódz, 90-302, Poland
Ostrowiec Swietokrzysk, 27-400, Poland
City of Tshwane, 0186, South Africa
Ekurhuleni, 1459, South Africa
Ekurhuleni, 1501, South Africa